Latest Period
Q1 2026
CUSIP: 457637700
Latest Period
Q1 2026
Institutions Reporting
8
Shares (Excl. Options)
319,301
Price
$0.64
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 8 institutions filings for Q1 2026.
Security key
457637700
Latest holder period
Q1 2026
13F holders
8
13D/G owners
2
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 457637700:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Squadron Capital Management LLC | 9.8% | $208,000 | 325,000 | Squadron Master Fund LP | 19 May 2026 | |||
| SABBY MANAGEMENT, LLC | 9.9% | $333,364 | 280,138 | SABBY MANAGEMENT, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 8 institutional investors reported holding 319,301 shares of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM). This represents 9.6% of the company’s total 3,316,327 outstanding shares.
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 319,301 | $206,034 | +$49,348 | $0.64 | 8 |
| 2025 Q4 | 227,043 | $240,666 | -$175,633 | $1.06 | 6 |
| 2025 Q3 | 303,584 | $665,240 | +$637,052 | $2.19 | 8 |
| 2025 Q2 | 8,470 | $28,508 | +$7,682 | $3.25 | 6 |
| 2025 Q1 | 6,408 | $13,264 | -$185,585 | $2.04 | 4 |
| 2024 Q4 | 48,870 | $226,645 | +$226,645 | $4.87 | 4 |